DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PHERGAIN
Chemotherapy-ree trastuzumab and pertuzumab (PH) in HER2[+] breast cancer (BC): FDG-PET response-adapted strategy: the PHERGAIN study
BREAST
SABCS
2017
SLLIP
Prospective comparision of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, NSCLC patients - Spanish Lung Liquid vs. Invasive Biopsy Program
LUNG
ESMO
2017
PARSIFAL
A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palocicib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC)
BREAST
ESMO
2016
MERIBEL
MERIBEL study: first line eribulin for taxane resistant HER2[-] metastatic breast cancer (MBC) patients
BREAST
ESMO
2016
POLEN
Preoperative olaparib in early-stae endometrial cancer (EC): a window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)
ENDOMETRIUM
ESMO
2016
THELMA
Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC)
BREAST
SABCS
2016
PIQHASSO
Open label, non-randomized, multicenter phase I/IIA study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2(-) and triple-negative breast cancer (TNBC) (PIQHASSO study)
BREAST
SABCS
2016
ATHENA
Prognostic relevance of prior endocrine treatments in overall survival (OS) at the time of first line chemotherapy in ER[+]/HER2[-] advanced breast cancer (ABC) patients
BREAST
SABCS
2015
MERIBEL
MERIBEL study: efficacy of eribulin in first line of taxane resistant patients with HER2-negative metastatic breast cancer
BREAST
SABCS
2014
ATHENA
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial
BREAST
(Journal) The Breast
2014
TRASTYVERE
Preliminary results from TRASTYVERE study: a retrospective analysis of heavily pretreated HER2-positive meastatic breast cancer (MBC) patients treated in Spain with lapatinib pluse trastuzumab as compassive therapy
BREAST
SEOM
2014
TRASTYVERE
Preliminary results from TRASTYVERE study: a retrospective analysis of heavily pretreated HER2-positive meastatic breast cancer (MBC) patients treated in Spain with lapatinib pluse trastuzumab as compassive therapy
BREAST
ASCO
2014
Other MEDSIR related articles
